Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRZEMYSLAW W TWARDOWSKI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1942317987
CMS profile
269277
Location
SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$122,114.34

174 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRZEMYSLAW W TWARDOWSKI

NPI 1942317987 · CMS profile ID 269277

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942317987?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRZEMYSLAW W TWARDOWSKI, NPI 1942317987, CMS profile ID 269277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942317987?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PRZEMYSLAW W TWARDOWSKI, NPI 1942317987, CMS profile ID 269277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942317987?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PRZEMYSLAW W TWARDOWSKI, NPI 1942317987, CMS profile ID 269277, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–174 of 174 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1942317987?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

174 matching records · $122,114.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 174 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–174 of 174.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $18.9403/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695439287 CMS
Astellas Pharma US Inc $37.0303/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655785599 CMS
Astellas Pharma US Inc $247.1203/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655785601 CMS
Astellas Pharma US Inc $4,655.0003/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655785605 CMS
Astellas Pharma US Inc $931.9203/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655785607 CMS
Bayer HealthCare Pharmaceuticals Inc. $30.0003/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628468931 CMS
Bayer HealthCare Pharmaceuticals Inc. $30.0003/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628490711 CMS
Bayer HealthCare Pharmaceuticals Inc. $173.9003/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628490827 CMS
Bayer HealthCare Pharmaceuticals Inc. $173.9003/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628492595 CMS
Bayer HealthCare Pharmaceuticals Inc. $453.7303/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628491835 CMS
GENZYME CORPORATION $1,154.0002/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694281127 CMS
GENZYME CORPORATION $117.6102/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694005671 CMS
GENZYME CORPORATION $4,328.0002/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694005689 CMS
GENZYME CORPORATION $794.1702/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694005691 CMS
Merck Sharp & Dohme Corporation $17.6402/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695329707 CMS
AstraZeneca UK Limited $27.3002/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685312277 CMS
AstraZeneca UK Limited $125.0002/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685810765 CMS
Genentech USA, Inc. $100.0002/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681396017 CMS
Janssen Biotech, Inc. $102.7902/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658761044 CMS
Merck Sharp & Dohme Corporation $19.1901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695321423 CMS
Janssen Biotech, Inc. $14.6801/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658761039 CMS
Dendreon Pharmaceuticals LLC $11.7001/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703771621 CMS
Janssen Biotech, Inc. $11.7601/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658761035 CMS
Array BioPharma Inc. $23.5801/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700971985 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $122,114.34 174
PY2020 $94,176.19 104
PY2021 $74,335.41 111
PY2022 $201,003.03 206
PY2023 $193,290.28 218
PY2024 $167,493.49 178
PY2025 $142,364.66 158

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $314.64 2
PY2025 Principal investigator $1,121,216.60 157
PY2024 Recipient $191.83 1
PY2024 Principal investigator $944,798.82 152
PY2023 Principal investigator $1,438,293.19 94
PY2022 Principal investigator $606,833.96 48
PY2021 Principal investigator $1,100,735.70 75
PY2020 Principal investigator $523,039.35 167
PY2019 Principal investigator $224,500.20 190

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

159 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 12/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411618
Principal investigator 1 Merck Sharp & Dohme LLC $18,435.62 12/31/2025 Non-covered Recipient Entity
Providence Saint John's Health Center
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926693
Principal investigator 1 Merck Sharp & Dohme LLC $22,150.54 12/31/2025 Non-covered Recipient Entity
John Wayne Cancer Institute
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927699
Principal investigator 1 Merck Sharp & Dohme LLC $11,878.00 12/31/2025 Non-covered Recipient Entity
Providence Saint John's Health Center
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1232931216
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $540.00 12/16/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411626
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 12/16/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411652
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 12/16/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411716
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 12/10/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411642
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,889.00 12/10/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411676
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $395.00 12/10/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411682
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 12/10/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411698
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 12/10/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411710
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,589.00 12/10/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411718
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 12/10/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411720
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $253.50 12/10/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411742
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 12/01/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411606
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 12/01/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411624
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 12/01/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411656
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 12/01/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411684
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 12/01/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411696
Principal investigator 1 Novartis Pharmaceuticals Corporation $62,755.64 12/01/2025 Non-covered Recipient Entity
SAINT JOHNS CANCER INSTITUTE
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer No dispute reported 06/30/2026 1190303123
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 11/14/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409560
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 11/14/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409806
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $405.00 11/14/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409838
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.00 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409920
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.00 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409924
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.00 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409998
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $108.00 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410040
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $150.00 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410062
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410076
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.00 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410192
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.00 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410212
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.00 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410228
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.00 10/31/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410248
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $65.00 10/27/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409974
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 10/15/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410256
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 10/15/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410292
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,705.79 10/15/2025 Non-covered Recipient Entity
PROVIDENCE SAINT JOHNS HEALTH CENTER
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190305247
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 10/03/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409938
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 10/03/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409976
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 10/03/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409996
Principal investigator 1 Merck Sharp & Dohme LLC $4,542.00 09/18/2025 Non-covered Recipient Entity
Providence Saint John's Health Center
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926691
Principal investigator 1 Organon Llc $468.00 09/18/2025 Non-covered Recipient Entity
John Wanye Cancer Institute
3475-587 No dispute reported 06/30/2026 1173042718
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 09/17/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410382
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 09/17/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410468
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 09/17/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410534
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 09/17/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410754
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 09/17/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410782
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 09/17/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411006
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 09/17/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411024
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $405.00 09/17/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411378
Recipient Regeneron Pharmaceuticals, Inc. $211.54 09/12/2025 Covered Recipient Physician A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184123622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44.55 08/14/2025 Non-covered Recipient Entity
SAINT JOHNS CANCER INSTITUTE
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184228461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,081.35 08/14/2025 Non-covered Recipient Entity
SAINT JOHNS CANCER INSTITUTE
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184228463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.90 08/14/2025 Non-covered Recipient Entity
SAINT JOHNS CANCER INSTITUTE
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184228465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,988.28 07/08/2025 Non-covered Recipient Entity
SAINT JOHNS CANCER INSTITUTE
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184213365
Principal investigator 1 Janssen Research & Development, LLC $2,700.00 06/18/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180445
Principal investigator 1 Merck Sharp & Dohme LLC $82,800.00 06/10/2025 Non-covered Recipient Entity
Saint John's Cancer Institute
A Phase 1,1b, Open-Label, Study of ANK-101 Administered as a Single Agent in Participants with Advanced Cutaneous, Subcutaneous, Soft Tissue or Nodal Tumors or in Combination with Pembrolizumab in Participants with Advanced Mucosal Melanoma No dispute reported 06/30/2026 1232932417
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 06/04/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407946
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $405.00 06/04/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408004
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 06/04/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408478
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 06/04/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408496
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407400
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407402
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407406
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407414
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407428
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $400.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407448
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407470
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407510
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $250.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407512
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407518
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407520
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407528
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407530
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $400.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407538
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407540
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407548
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407550
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407556
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407564
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407566
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407568
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407642
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407646
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407648
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407670
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407688
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $279.31 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407702
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407712
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 05/26/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407776
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $500.00 05/21/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407786
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,516.00 04/28/2025 Non-covered Recipient Entity
PROVIDENCE SAINT JOHNS HEALTH CENTER
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer No dispute reported 06/30/2026 1190305243
Principal investigator 1 Janssen Research & Development, LLC $2,076.00 04/24/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180306
Principal investigator 1 Janssen Research & Development, LLC $9,677.00 04/24/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180356
Principal investigator 1 Janssen Research & Development, LLC $4,760.00 04/24/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180454
Principal investigator 1 Janssen Research & Development, LLC $5,124.00 04/24/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180484
Principal investigator 1 Janssen Research & Development, LLC $33,688.00 04/24/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180491
Principal investigator 1 Janssen Research & Development, LLC $2,739.00 04/24/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180690
Principal investigator 1 Janssen Research & Development, LLC $519.00 04/11/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180390
Principal investigator 1 Janssen Research & Development, LLC $519.00 04/11/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180422
Principal investigator 1 Janssen Research & Development, LLC $4,625.00 04/11/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180476
Principal investigator 1 Janssen Research & Development, LLC $338.00 04/11/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180575
Principal investigator 1 Janssen Research & Development, LLC $519.00 04/11/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180682
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 03/24/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403181
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 03/24/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225407020
Principal investigator 1 AstraZeneca UK Limited $75,696.63 03/05/2025 Non-covered Recipient Entity
SAINT JOHNS CANCER INSTITUTE
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185553581
Principal investigator 1 Janssen Research & Development, LLC $45,947.00 03/05/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180415
Recipient Regeneron Pharmaceuticals, Inc. $103.10 03/04/2025 Covered Recipient Physician A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression No dispute reported 06/30/2026 1184123620
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225402513
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225402515
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225402727
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,589.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225402951
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225402953
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225402955
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225402963
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403103
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403535
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403659
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403661
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403673
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404046
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404321
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404602
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404604
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404956
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404958
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405018
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405352
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405354
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405416
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405580
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405582
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $14,956.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405584
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $14,956.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405874
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406258
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406342
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406344
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406346
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406348
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $14,956.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406360
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406362
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406364
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406416
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406636
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406638
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406686
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406688
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406690
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406716
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,595.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406718
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,478.00 02/28/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406880
Principal investigator 1 Janssen Research & Development, LLC $5,986.44 02/14/2025 Non-covered Recipient Entity
Saint Johns Cancer Inst
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175180290
Principal investigator 1 AstraZeneca Pharmaceuticals LP $172,576.91 02/05/2025 Non-covered Recipient Entity
SAINT JOHNS CANCER INSTITUTE
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185553583
Principal investigator 1 Merck Sharp & Dohme LLC $2,500.00 02/05/2025 Non-covered Recipient Entity
Providence Saint John's Health Center
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1232931024
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,286.95 01/29/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403781
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $405.00 01/29/2025 Non-covered Recipient Entity
New Mexico Cancer Center Admin Office
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405626
Principal investigator 1 Novartis Pharmaceuticals Corporation $69,547.90 01/15/2025 Non-covered Recipient Entity
PROVIDENCE SAINT JOHNS HEALTH CENTER
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190305245
Principal investigator 1 Novartis Pharmaceuticals Corporation $206,658.00 01/07/2025 Non-covered Recipient Entity
SAINT JOHNS CANCER INSTITUTE
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190304135